<DOC>
	<DOCNO>NCT02011997</DOCNO>
	<brief_summary>This Prospective , open-label , parallel , multi-center , Phase III randomize trial evaluate efficacy safety video-assisted thoracoscopic segmentectomy versus Lobectomy treat patient Lung adenocarcinoma situ microinvasion .</brief_summary>
	<brief_title>Comparison cVATS Segmentectomy Versus Lobectomy Lung Adenocarcinoma Situ With Microinvasion</brief_title>
	<detailed_description>Lobectomy long consider standard procedure early-stage lung cancer , minimally invasive technique demonstrate associated superior outcome compare lobectomy thoracotomy . u segmentectomy investigation select patient small tumor , use minimally invasive strategy applicable well . This nationwide , multicenter , prospective , randomized open phase III study cVATS ( complete Video-assisted Thoracoscopic Surgery ) segmentectomy versus Lobectomy stage IA non-small cell lung cancer ( NSCLC ) patient Lung adenocarcinoma situ microinvasion , aim evaluate relapse free survival 5 year overall survival ( OS ) rate two type surgery . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo cVATS lobectomy . - Arm II : Patients undergo cVATS segmentectomy . Patients follow every 3 month within first year , annually 5 year postoperatively .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma Situ</mesh_term>
	<criteria>Preoperative criterion : peripheral nonsmall cell lung cancer , large 2 cm maximal diameter , lymph node metastasis , FEV1 % &gt; 50 % ( FEV1 : Forced Expiratory Volume 1 second ) ; Preoperative imaging : pure groundglass mixed groundglass nodule ( partsolid , solid area &lt; 0.5cm ) ; Followup duration last 3 month , HRCT ( HRCT : highresolution compute tomography ) lesion maximum diameter measure three time take average , meet criterion clinical surgical indication ; Intraoperative criterion : histologically confirm NSCLC , adenocarcinoma situ microinvasion ; No prior ipsilateral thoracotomy ; No prior antineoplastic therapy ; EOCG Performance status 02 ; Sufficient organ function ; Written inform consent . Active bacterial fungous infection ; Simultaneous prior ( within past 5 year ) malignant disease ; Interstitial pneumonitis , pulmonary fibrosis , severe COPD ( COPD : chronic obstructive pulmonary disease ) ; Abnormal Psychosis ; Uncontrollable diabetes mellitus ; History severe cardiovascular disease ; Any condition , opinion investigator might interfere evaluation objective .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>